Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
Would you offer chemotherapy to a young female s/p TAH-BSO with a pure mucinous, grade 3, T1cN0, HR+ HER2- breast cancer and an OncotypeDx score between 21-25?
Oncotype 24, <50 years old.
Related Questions
What are best practices for oncologists during the national platinum shortage?
What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?
In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
How would you approach a cT4 cN2 (22 cm in size) TNBC that shrank to 9 cm with KN-522 regimen but remains inoperable at the end of treatment?
In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
How do you approach the discussion with a patient who is seeking proton therapy for early stage breast cancer?
